How were Oyster Point Pharma's earnings last quarter?

Oyster Point Pharma, Inc. (NASDAQ:OYST) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.48. The company earned $17.94 million during the quarter. Oyster Point Pharma had a negative net margin of 901.99% and a negative trailing twelve-month return on equity of 490.33%. During the same period last year, the business earned ($0.63) EPS.

What other stocks do shareholders of Oyster Point Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK) , Pfizer (PFE) , Akero Therapeutics (AKRO) , Walt Disney (DIS) , Energy Transfer (ET) , Fulcrum Therapeutics (FULC) , Johnson & Johnson (JNJ) , Occidental Petroleum (OXY) and vTv Therapeutics (VTVT) .

When did Oyster Point Pharma IPO?

Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

NASDAQ:OYST

Oyster Point Pharma (OYST) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free OYST Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $11.17
▼
$11.17
50-Day Range: $11.08
▼
$11.20
52-Week Range: $3.46
▼
$19.00

Volume: 330 shs
Average Volume: 212,171 shs
Market Capitalization: $299.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Oyster Point Pharma alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Oyster Point Pharma Stock (NASDAQ:OYST)

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

OYST Stock News Headlines

April 19, 2024 | bizjournals.com

As biotech vacancies hit 20%, oversupply of space could crunch crossover developers

April 15, 2024 | nytimes.com

The 25 Best Restaurants in Boston Right Now

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 3, 2024 | msn.com

Portions of Mobile Bay reopen for oyster harvesting

March 29, 2024 | msn.com

The world is indeed your oyster at the beach in all kinds of ways

March 28, 2024 | msn.com

The 10 Best Oyster Restaurants In Atlanta

March 28, 2024 | msn.com

Broad Street Oyster Co.’s Legendary Lobster Rolls Land at Ghirardelli Square Tomorrow

March 24, 2024 | msn.com

What’s the Best Substitute for Oyster Sauce? We Have 10 Tasty Swaps

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 9, 2024 | sports.yahoo.com

Sophomore Bussiere shines in net for Oyster River/Portsmouth in state championship loss

March 6, 2024 | yahoo.com

Aww shucks!!! Oyster recycling program reaches major milestone

March 5, 2024 | uk.finance.yahoo.com

Biotechnology Licensing Deals Analysis Reveals Key Trends and Major Agreements from 2019-2024

February 28, 2024 | uk.finance.yahoo.com

Q4 2023 Viatris Inc Earnings Call

February 22, 2024 | news.yahoo.com

Oyster River School Board candidate John Colwell

February 18, 2024 | thestreet.com

Oyster Point Pharma Inc.

February 16, 2024 | yahoo.com

New restaurant: Grill and oyster bar features burgers, fresh seafood, raw bar

February 16, 2024 | sports.yahoo.com

Thursday Seacoast roundup: Oyster River/Portsmouth's Metcalf nets two in girls hockey win

February 9, 2024 | yahoo.com

What Is Oyster Pie?

February 8, 2024 | bizjournals.com

Kilroy's mega project at Oyster Point is facing a 6 month delay. Here's why

January 25, 2024 | msn.com

Oyster Sales Plummet at LA Restaurants Amid Unclear Guidance From Health Officials

January 23, 2024 | news.yahoo.com

Oyster roast helps further land trust mission

January 21, 2024 | msn.com

January 20, 2024 | msn.com

Avoid All Oysters Imported from Mexico, Health Officials Warn, as Norovirus Cases Spread

January 18, 2024 | yahoo.com

Raw oyster illnesses traced to parts of Mexico: Public Health

January 17, 2024 | msn.com

Raw Oyster Warning Expanded Across SoCal After Dozens Sickened

January 16, 2024 | news.yahoo.com

Warning over raw oyster consumption expands to more parts of Southern California

January 16, 2024 | msn.com

Alabama wild oyster harvest declines; predator ‘infestation’ blamed

See More Headlines

Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:OYST
CUSIP: N/A
CIK: 1720725
Web: www.oysterpointrx.com
Phone: 609-382-9032
Fax: N/A
Employees: 303
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($6.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-100,660,000.00
Net Margins: -901.99%
Pretax Margin: -901.99%
Return on Equity: -490.33%
Return on Assets: -108.29%

Debt

Debt-to-Equity Ratio: 8.49
Current Ratio: 3.35
Quick Ratio: 3.11

Sales & Book Value

Annual Sales: $24.54 million
Price / Sales: 12.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.80 per share
Price / Book: 2.94

Miscellaneous

Outstanding Shares: 26,844,000
Free Float: 22,039,000
Market Cap: $299.85 million
Optionable: Not Optionable
Beta: 1.31

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Jeffrey Nau MMS (Age 47)
Ph.D., Pres, CEO & Director
Comp: $962.85k
Mr. Daniel Lochner M.B.A. (Age 40)
CFO & Chief Bus. Officer
Comp: $642k
Mr. George Donato M.B.A.
Sr. VP of CMC & Operations
Dr. Eric Carlson Ph.D.
Chief Scientific Officer
Arty Ahmed
VP of Investor relations
Mr. Barry Rosenfeld J.D.
Sr. VP & Gen. Counsel
Ms. Raegan A. McClain CCEP
J.D., L.L.M., Chief Compliance & Privacy Officer
Ms. Karen Castillo-Paff
VP of Communications & PR
Mr. Dave Benadon
Chief HR Officer
Ms. Loni Da Silva M.S.
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

OYST Stock Analysis - Frequently Asked Questions

How were Oyster Point Pharma's earnings last quarter?: Oyster Point Pharma, Inc. (NASDAQ:OYST) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.48. The company earned $17.94 million during the quarter. Oyster Point Pharma had a negative net margin of 901.99% and a negative trailing twelve-month return on equity of 490.33%. During the same period last year, the business earned ($0.63) EPS.
What other stocks do shareholders of Oyster Point Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT).
When did Oyster Point Pharma IPO?: Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

This page (NASDAQ:OYST) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oyster Point Pharma (OYST) Stock Price, News & Analysis

About Oyster Point Pharma Stock (NASDAQ:OYST)

OYST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OYST Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info